Latest News for: gsk

Edit

GSK plc (the 'Company') Transaction notification (Form 6-K) (GSK plc)

Public Technologies 16 Jan 2026
GSK plc ... GSK plc (the 'Company') ... GSK plc ... GSK plc ... GSK plc ... GSK plc ... GSK plc ... About GSK. GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com ... GSK plc.
Edit

Bial Portela notifies the acquisition of control over a set of GSK assets (Portuguese Competition Authority)

Public Technologies 16 Jan 2026
Bial Portela notifies the acquisition of control over a set of GSK assets.
Edit

Transaction notification (Form 6-K) (GSK plc)

Public Technologies 15 Jan 2026
GSK plc ... GSK plc (the 'Company') ... GSK plc ... GSK plc ... About GSK. GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com ... GSK plc ... behalf of GSK plc.
Edit

Q4 2025 pre announcement aide memoire (GSK plc)

Public Technologies 14 Jan 2026
GSK has prepared this Q4 2025 pre-announcement aide memoire per our standard prior practice ... GSK upgrades its full-year 2025 guidance at constant exchange rates (CER) ... GSK enters agreement with the U.S ... GSK enters agreement with U.S ... GSK ... GSK ... GSK ... GSK ... GSK.
Edit

Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s ...

Business Wire 12 Jan 2026
SMMT) today announced it has entered into a clinical trial collaboration with GSK plc (“GSK”, ...
Edit

Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC) (Summit Therapeutics Inc)

Public Technologies 12 Jan 2026
SMMT) today announced it has entered into a clinical trial collaboration with GSK plc ("GSK", LSE/NYSE. GSK) to evaluate ivonescimab, a novel, investigational PD-1 / VEGF bispecific antibody, ...
Edit

GSK Licenses Noetik’s AI Foundation Models in Anchor Partnership to Transform Cancer Therapeutic Research and Development

Hastings Tribune 08 Jan 2026
SAN FRANCISCO--(BUSINESS WIRE)--Jan 8, 2026-- ... .
Edit

GSK announces positive results from B-Well 1 and B-Well 2 phase III trials for bepirovirsen, a potential first-in-class treatment for chronic hepatitis B (GSK plc)

Public Technologies 07 Jan 2026
GSK plc (LSE/NYSE. GSK) today ... Tony Wood, Chief Scientific Officer, GSK, said. ... GSK licensed bepirovirsen from Ionis and collaborated with them on its development ... About GSK ... Find out more at gsk.com.
Edit

Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 ...

Enid News & Eagle 07 Jan 2026
CARLSBAD, Calif.--(BUSINESS WIRE)--Jan 7, 2026-- ... .
Edit

GSK's Shingrix (Recombinant Zoster Vaccine) prefilled syringe presentation approved by the European Commission (Form 6-K) (GSK plc)

Public Technologies 07 Jan 2026
GSK plc ... GSK's Shingrix (Recombinant Zoster Vaccine) prefilled syringe presentation approved by the European Commission ... GSK plc (LSE/NYSE ... Tony Wood, Chief Scientific Officer, GSK, said ... About GSK ... Find out more at www.gsk.com. GSK enquiries ... [4] GSK.
Edit

Helix Announces Multi-Year Strategic Collaboration with GSK to Drive Precision Medicine Development

PR Newswire 07 Jan 2026
7, 2026 /PRNewswire/ -- Helix, the leading enterprise genomics company, today announced a multi-year strategic collaboration with GSK, the global biopharma company. This agreement provides GSK ... GSK Logo.
Edit

GSK announces positive results from B-Well 1 and B-Well 2 phase III trials for bepirovirsen, a potential first-in-class treatment for chronic hepatitis B (Form 6-K) (GSK plc)

Public Technologies 07 Jan 2026
GSK plc ... GSK announces positive results from B-Well 1 and B-Well 2 phase III trials for bepirovirsen, a potential first-in-class treatment for chronic hepatitis B ... GSK plc (LSE/NYSE ... Tony Wood, Chief Scientific Officer, GSK, said. ... About GSK ... GSK plc.
Edit

GSK’s Shingrix (Recombinant Zoster Vaccine) prefilled syringe presentation approved by the European Commission (GSK plc)

Public Technologies 07 Jan 2026
GSK plc (LSE/NYSE. GSK) today announced the European Commission's (EC) approval of Shingrix (GSK's Recombinant Zoster Vaccine or RZV) in a prefilled syringe ... Tony Wood, Chief Scientific Officer, GSK, said ... Find out more at https.//www.gsk.com ... GSK.
Edit

Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B (Form 8-K) (Ionis Pharmaceuticals Inc)

Public Technologies 07 Jan 2026
) Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B ... IONS) partner GSK today ...
Edit

Hepatitis B Market to Witness Promising Upswing by 2034, DelveInsight Forecasts | Arbutus Biopharma, GSK/Ionis ...

GetNews 07 Jan 2026
The Key Hepatitis B Companies in the market include - Arbutus Biopharma, GSK/Ionis Pharmaceuticals, Vir Biotechnology, Dong-A ST Co., Ltd., Barinthus Biotherapeutics, GC ... GSK/Ionis Pharmaceuticals.

Article Search

tools
×
×
×
×